ROLE OF PET/MRI IN HEMATOLOGIC MALIGNANCIES: PRELIMINARY OBSERVATIONS
(Abstract release date: 05/19/16)
EHA Library. Mendez G. 06/09/16; 134598; PB1698
Dr. Guy Mendez
Contributions
Contributions
Abstract
Abstract: PB1698
Type: Publication Only
Background
Hybrid imaging using simultaneous PET / MRI could be a valuable diagnostic modality for the staging and follow-up of patients with hematologic malignancies. Since the availability of this technique is currently restricted to a small number of centers, data available in this setting is still limited.
Aims
Our objective is to analyze the results and potential advantages of PET / MRI in hematologic malignancies.
Methods
A total of 30 PET/MRI studies were performed at our institution using a Biograph mMR device. Informed consent, which included use of clinical data, was obtained before every procedure. PET / MRI was performed 45 minutes after injection of 18F-FDG. Images were obtained from orbital region to proximal third femur. Magnetic Resonance was obtained by HASTE sequencing.
Results
A total of 21 patients were studied. Median age was 62 years (range 35-89).Patients’ diagnoses were: Diffuse Large B Cell Lymphoma (8 patients); Follicular Lymphoma (3); Multiple Myeloma (2); Primary Central Nervous System Lymphoma (2); Hodgkin Lymphoma (3); Plasmacytoma (1) and other Low grade Lymphomas (2). In 7 patients (23%) PET / MRI was used for initial staging, and in 11 patients (37%) it was used for follow-up, comparing previous results with other staging techniques (CT scan / PET-CT). In 3 patients (12%) the PET / MRI was used to study possible relapse of the disease. In 9 patients (30%) a second PET / MRI was performed for either follow-up (6 patients, 20%), or to evaluate potential relapse (3 patients,10%). Of all procedures performed, PET / MRI was useful for establishing initial stage (6 patients, 20%); confirm response to therapy (14 patients. 46%); and prove disease relapse (3 patients 10%). Finally, in 7 patients (23%) in whom conventional imaging had shown residual disease, PET / MRI was able to demonstrate complete remission.
Conclusion
Taken together, our results suggest that PET / MRI is a promising technique which may improve diagnostic accuracy, with a reduction of radiation dose in patients with hematologic malignancies. Further studies are needed in order to validate this technique for clinical use.
Session topic: E-poster
Keyword(s): Hematological malignancy, Magnetic resonance imaging, PET
Type: Publication Only
Background
Hybrid imaging using simultaneous PET / MRI could be a valuable diagnostic modality for the staging and follow-up of patients with hematologic malignancies. Since the availability of this technique is currently restricted to a small number of centers, data available in this setting is still limited.
Aims
Our objective is to analyze the results and potential advantages of PET / MRI in hematologic malignancies.
Methods
A total of 30 PET/MRI studies were performed at our institution using a Biograph mMR device. Informed consent, which included use of clinical data, was obtained before every procedure. PET / MRI was performed 45 minutes after injection of 18F-FDG. Images were obtained from orbital region to proximal third femur. Magnetic Resonance was obtained by HASTE sequencing.
Results
A total of 21 patients were studied. Median age was 62 years (range 35-89).Patients’ diagnoses were: Diffuse Large B Cell Lymphoma (8 patients); Follicular Lymphoma (3); Multiple Myeloma (2); Primary Central Nervous System Lymphoma (2); Hodgkin Lymphoma (3); Plasmacytoma (1) and other Low grade Lymphomas (2). In 7 patients (23%) PET / MRI was used for initial staging, and in 11 patients (37%) it was used for follow-up, comparing previous results with other staging techniques (CT scan / PET-CT). In 3 patients (12%) the PET / MRI was used to study possible relapse of the disease. In 9 patients (30%) a second PET / MRI was performed for either follow-up (6 patients, 20%), or to evaluate potential relapse (3 patients,10%). Of all procedures performed, PET / MRI was useful for establishing initial stage (6 patients, 20%); confirm response to therapy (14 patients. 46%); and prove disease relapse (3 patients 10%). Finally, in 7 patients (23%) in whom conventional imaging had shown residual disease, PET / MRI was able to demonstrate complete remission.
Conclusion
Taken together, our results suggest that PET / MRI is a promising technique which may improve diagnostic accuracy, with a reduction of radiation dose in patients with hematologic malignancies. Further studies are needed in order to validate this technique for clinical use.
Session topic: E-poster
Keyword(s): Hematological malignancy, Magnetic resonance imaging, PET
Abstract: PB1698
Type: Publication Only
Background
Hybrid imaging using simultaneous PET / MRI could be a valuable diagnostic modality for the staging and follow-up of patients with hematologic malignancies. Since the availability of this technique is currently restricted to a small number of centers, data available in this setting is still limited.
Aims
Our objective is to analyze the results and potential advantages of PET / MRI in hematologic malignancies.
Methods
A total of 30 PET/MRI studies were performed at our institution using a Biograph mMR device. Informed consent, which included use of clinical data, was obtained before every procedure. PET / MRI was performed 45 minutes after injection of 18F-FDG. Images were obtained from orbital region to proximal third femur. Magnetic Resonance was obtained by HASTE sequencing.
Results
A total of 21 patients were studied. Median age was 62 years (range 35-89).Patients’ diagnoses were: Diffuse Large B Cell Lymphoma (8 patients); Follicular Lymphoma (3); Multiple Myeloma (2); Primary Central Nervous System Lymphoma (2); Hodgkin Lymphoma (3); Plasmacytoma (1) and other Low grade Lymphomas (2). In 7 patients (23%) PET / MRI was used for initial staging, and in 11 patients (37%) it was used for follow-up, comparing previous results with other staging techniques (CT scan / PET-CT). In 3 patients (12%) the PET / MRI was used to study possible relapse of the disease. In 9 patients (30%) a second PET / MRI was performed for either follow-up (6 patients, 20%), or to evaluate potential relapse (3 patients,10%). Of all procedures performed, PET / MRI was useful for establishing initial stage (6 patients, 20%); confirm response to therapy (14 patients. 46%); and prove disease relapse (3 patients 10%). Finally, in 7 patients (23%) in whom conventional imaging had shown residual disease, PET / MRI was able to demonstrate complete remission.
Conclusion
Taken together, our results suggest that PET / MRI is a promising technique which may improve diagnostic accuracy, with a reduction of radiation dose in patients with hematologic malignancies. Further studies are needed in order to validate this technique for clinical use.
Session topic: E-poster
Keyword(s): Hematological malignancy, Magnetic resonance imaging, PET
Type: Publication Only
Background
Hybrid imaging using simultaneous PET / MRI could be a valuable diagnostic modality for the staging and follow-up of patients with hematologic malignancies. Since the availability of this technique is currently restricted to a small number of centers, data available in this setting is still limited.
Aims
Our objective is to analyze the results and potential advantages of PET / MRI in hematologic malignancies.
Methods
A total of 30 PET/MRI studies were performed at our institution using a Biograph mMR device. Informed consent, which included use of clinical data, was obtained before every procedure. PET / MRI was performed 45 minutes after injection of 18F-FDG. Images were obtained from orbital region to proximal third femur. Magnetic Resonance was obtained by HASTE sequencing.
Results
A total of 21 patients were studied. Median age was 62 years (range 35-89).Patients’ diagnoses were: Diffuse Large B Cell Lymphoma (8 patients); Follicular Lymphoma (3); Multiple Myeloma (2); Primary Central Nervous System Lymphoma (2); Hodgkin Lymphoma (3); Plasmacytoma (1) and other Low grade Lymphomas (2). In 7 patients (23%) PET / MRI was used for initial staging, and in 11 patients (37%) it was used for follow-up, comparing previous results with other staging techniques (CT scan / PET-CT). In 3 patients (12%) the PET / MRI was used to study possible relapse of the disease. In 9 patients (30%) a second PET / MRI was performed for either follow-up (6 patients, 20%), or to evaluate potential relapse (3 patients,10%). Of all procedures performed, PET / MRI was useful for establishing initial stage (6 patients, 20%); confirm response to therapy (14 patients. 46%); and prove disease relapse (3 patients 10%). Finally, in 7 patients (23%) in whom conventional imaging had shown residual disease, PET / MRI was able to demonstrate complete remission.
Conclusion
Taken together, our results suggest that PET / MRI is a promising technique which may improve diagnostic accuracy, with a reduction of radiation dose in patients with hematologic malignancies. Further studies are needed in order to validate this technique for clinical use.
Session topic: E-poster
Keyword(s): Hematological malignancy, Magnetic resonance imaging, PET
{{ help_message }}
{{filter}}